ERIC TP53 Network activities and outcomes. Sarka Pospisilova
|
|
- Jane Stewart
- 5 years ago
- Views:
Transcription
1 ERIC TP53 Network activities and outcomes Sarka Pospisilova
2 ERIC TP53 NETWORK 11 Training Centres 3 Certifying Centres Uppsala/Stockholm Belfast Copenhagen Amsterdam Paris Ulm Novara Brno Bellinzona Salamanca Thessaloniki
3 ERIC TP53 NETWORK STRUCTURE: Training Centres Stephan Stilgenbauer, Eugen Tausch, Ulm, Germany Sarka Pospisilova, Jitka Malcikova, Brno, Czech Republic Richard Rosenquist, Stockholm, Sweden and Nordic countries Kostas Stamatopoulos, Thessaloniki, Greece Gianluca Gaidano, Novara, Italy Fred Davi', Paris, France Ramon Garcia Sanz, Salamanca, Spain Carsten Niemann, Copenhagen, Denmark Arnon Kater, Amsterdam, Netherlands Davide Rossi, Bellinzona, Switzerland David Gonzalez de Castro, Belfast, U.K. Certifying Centres Stephan Stilgenbauer, Eugen Tausch, Ulm, Germany Sarka Pospisilova, Jitka Malcikova, Sarka Pavlova, Brno, Czech Rep. Richard Rosenquist, Lesley Ann Sutton, Uppsala/Stockholm, Sweden
4 Why is TP53 dysfunction so important in CLL? Antioncogene TP53 = "the guardian of the genome" Conserves genetic stability by preventing genome mutation TP53 gene is located on the short arm of chromosome 17 (17p13.1) The p53 protein is crucial for regulation of the cell cycle arrest or apoptosis Tumors with p53 dysfunction - bad prognosis and poor treatment response TP53 dysfunction in CLL - del(17p) and/or TP53 mutation The most important independent prognostic marker High risk of progression within 1-2 years Median overall survival 3-5 years Frequency of TP53 aberrations increases with advanced disease stage and therapy Important predictive marker (resistance to FCR, alkylating agents, purine analogues ) Valid also in novel mutation era New therapeutic options (inhibition of BcR signaling, Bcl2 inhibition)
5 Types of TP53 defects in CLL Del(17p) & TP53 mutation del(17p) sole TP53 mutation sole Frequency increases during disease development Related to previous therapy
6 Independent prognostic impact of del(17p) and TP53 mutations Zenz et al. Blood 2008 Dicker et al. Leukemia 2009 Rossi et al. CCR, 2009 Malcikova et al. Blood, 2009 Stengel et al, Leukemia 2017 GCLLSG CLL4 trial (F vs FC) Zenz et al. JCO, 2010 CLL8 trial (FC vs FCR) Stilgenbauer et al. Blood 2014 LRF CLL4 (Clb vs F vs FC) Gonzalez et al. JCO, 2011 Analysis of both del(17p) by FISH and TP53 mutation recommmended!
7 ERIC TP53 NETWORK ACTIVITIES 1) ERIC Recommendations on TP53 mutation analysis Updates 2) Organization of regular Certification rounds for TP53 mutation analysis 3) Organization of workshop ontp53 analysis (Brno 2015, Stresa 2017, ) ERIC TP53 web: Diagnostics a) Manual for TP53 mutational analysis b) TP53 Analysis Template Report Forms c) TP53 Certification Requirements d) Helpdesk (ERIC office + expert in charge) e) Free Software for Sanger Analysis Data GLASS - for detection and annotation of low - frequent somatic variants
8 ERIC Publications on TP53 analysis Comprehensive profiling and analysis of TP53 mutation in CLL TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. T Zenz, D Vollmer, M Trbusek, J Smardova, A Benner, T Soussi, H Helfrich, M Heuberger, P Hoth, M Fuge, T Denzel, S Häbe, J Malcikova, P Kuglik, S Truong, N Patten, L Wu, D Oscier, R Ibbotson, A Gardiner, I Tracy, K Lin, A Pettitt, S Pospisilova, J Mayer, M Hallek, H Döhner, S Stilgenbauer, European Research Initiative on CLL (ERIC): Leukemia, ERIC recommendations on TP53 mutation analysis in Chronic Lymphocytic Leukemia. Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, Cymbalista F, Eichhorst B, Hallek M, Döhner H, Hillmen P, van Oers M, Gribben J, Ghia P, Montserrat E, Stilgenbauer S, Zenz T.: Leukemia, Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. Te Raa GD, Malčiková J, Mraz M, Trbusek M, Le Garff-Tavernier M, Merle-Béral H, Greil R, Merkel O, Pospisilova S, Lin K, Pettitt AR, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP; European Research Initiative on CLL (ERIC): Brit. J. Haematology, Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go? Pospisilova S, Sutton LA, Malcikova J, Tausch E, Rossi D, Montserrat E, Moreno C, Stamatopoulos K, Gaidano G, Rosenquist R, Ghia P; European Research Initiative on CLL (ERIC): Haematologica, 2016.
9 ERIC Recommendations UPDATE 2017 Currently recommended methods: Sanger sequencing with or without prescreening Next generation sequencing Updated Recommendations Detailed recommendations Which material? Which exons? Methods Sanger sequencing, Next Generation sequencing Interpretation and reporting Manual for TP53 mutational analysis
10 ERIC Recommendations for TP53 Mutation Analysis in Chronic Lymphocytic Leukemia Update on Methodological Approaches and Results Interpretation J. Malcikova, E. Tausch, D. Rossi, L. A. Sutton, T. Soussi, T. Zenz, A.P. Kater, C. U. Niemann, D. Gonzalez, F. Davi, M. Gonzalez Diaz, C. Moreno, G. Gaidano, K. Stamatopoulos, R. Rosenquist, S. Stilgenbauer, P. Ghia, S. Pospisilova on behalf of the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) TP53 network Supplementary files: Report forms for reporting results of TP53 mutation analysis
11 ERIC recommendation Patients Sampling Always when deciding about treatment. Material Procedure Sanger sequencing NGS Interpretation and clinical reporting Type of material Anticoagulant Cells Nucleic acid Covered region Primers and PCR protocol Sequencing Peripheral blood (PB) EDTA or heparin (in case of PB) Mononuclear cells DNA Optimum: exons 2-11 (coding region), Minimum: exons 4-10, Always include splice sites (+/-2 intronic bp) Available in the IARC TP53 database: Both strands (forward + reverse) Notes and alternatives Bone marrow, lymph nodes suitable alternatives if PB lymphocyte count is <10x10 9 /l, e.g. in SLL/CLL. Fresh/frozen tissues are strongly preferred. When PB or BM contains <60-70% of lymphocytes, separation of CD19+ cells or using deep-ngs with low detection limit is recommended. RNA analysis carries a risk of omitting truncating/splice site variants. Variants found in introns at positions +2/-2 impair splicing. Data analysis Use software designed for somatic variant detection Free web-based software available on the ERIC website. Protocol Sequencing Data analysis Variant description Interpretation Polymorphisms and benign variants Limit of detection and clinical reporting Report form Table: Overview of ERIC recommendations for TP53 analysis. Amplicon or capture-based approaches are applicable. DNA input should be calculated with respect to the limit of detection. Testing the integrity of DNA is recommended Minimum of 100 reads per each position. Number of variant reads for reliable variant calling should be at least 10. Use software designed for somatic variant detection. Validated minimal limit of detection should be 10% VAF. Use HGVS nomenclature: Report the cdna and protein level including reference sequence. Check the detected variants using locus-specific database: IARC TP53 database: or TP53 web site: It is preferred not to include common polymorphisms and benign variants in the report to physicians. Report variants detectable by Sanger sequencing and variants present in >10% VAF if tested by NGS. Reporting variants between 5-10% VAF is acceptable only if explicitly stating that the clinical impact of minor subclonal mutations has not been conclusively documented. Template report form is available on the ERIC website. Several ready-to use kits involving TP53 analysis are commercially available. 99% minimum coverage percentage should be reported. Proper bioinformatics approach represents the most challenging part of NGS and no universal tool is currently available. If a rare variant or variant with preserved functionality is detected: 1) Repeat the analysis by starting from PCR to exclude analytical errors. 2) If the variant is confirmed, test the paired germline DNA. Using dbsnp for filtering out polymorphisms and neutral variants is strongly discouraged. There is not enough evidence for making therapeutic decisions based on the detection of mutations present in low variant allele frequency.
12 ERIC Certification on the assessment of TP53 mutations AIMS: For all laboratories performing the TP53 analysis in CLL validation of different techniques on TP53 mutation analysis Support the introduction of TP53 analysis in labs with less experience (to provide assurance of the results quality) Discuss the problematic issues and give individual recommendations Improve analysis harmonization and interaction between centers Provide an official document on the quality control assessment
13 ERIC Certified Centres from 4 rounds ( ) Round 1: 30 Round 2: 16 Round 3: 29 Round 4: 35 (3 centres participated in 2 rounds with different techniques) Total Number of Certified Centers: 107 (total number of applicants 135, 25 failed)
14 ERIC Certified Centres - 4 Rounds 107 Centres from 24 countries
15 ERIC Certification on the assessment of TP53 mutations TP53 Certification Requirements
16 Institution
17 ERIC Certification on the assessment of TP53 mutations ROUND 5 (2017): 23 participating centres from 16 countries
18 Round 5 List of Participating Centres: Austria Medical University of Vienna (Vienna) Hungary Semmelweis University (Budapest) Belgium UZ Leuven (Leuven) Hopital Erasme (Brussels) Italy University of Bari (Bari) Asst Papa Giovanni XXIII (Bergamo) Brasil Instituto Nacional de Cancer-INCA (Rio de Janeiro) Czech Republic University Hospital Brno (Brno) Denmark Odense University Hospital (Odense) Finland Tykslab (Torku) France (EFSBFC) (Besançon) CHU Bordeaux (Pessac) Germany AgenDix GmbH (Dresden) Labor Dr. Wisplinghoff (Cologne) MVZ Dr Eberhard & Partner Dortmund (Dortmund) Poland The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology MCMCC (Warsaw) Sweden Sahlgrenska University Hospital (Goteborg) Spain Hospital La Fé (Valencia) Switzerland Kantonsspital St.Gallen (St Gallen) The Netherlands UMC Utrecht - 2 departments (Utrecht) The United Kingdom John Radcliffe Hospital (Oxford) King s College Hospital London (London) Round 5 Results: Available in Dec 2017 (ASH meeting)
19 ERIC Certification on the assessment of TP53 mutations Round 6 - Expected deadline for applications: December 15, 2017 Centers Certified in the Round 1 should re-apply in Round 6 Material to be sent: DNA Certified methods: both Sanger sequencing and NGS, Not two methods in one round
20 ERIC TP53 Network Activity: Organization of workshops on TP53 analysis 1st ERIC Workshop on TP53 analysis in CLL (Brno, 2015) 131 participants from 23 countries
21 2nd ERIC Workshop on TP53 analysis in CLL (Stresa, 2017) 134 participants (26 invited speakers, chairs, tutors)
22 ERIC TP53 Workshop Stresa Registration Questionnaire Output 3% 1% 19% 19% 58% 94% Sanger only 4% Sanger + MLPA 2% Sanger + Functional Sanger NGS Sanger + NGS FISH 96% 38% Functional
23 ERIC TP53 Survey Includes both clinical and laboratory questions Aim: better understanding of TP53 analysis and treatment implications of TP53 variants in CLL patients in clinical and laboratory practice More information on survey results will be presented in several lectures this afternoon Supported by Gilead
24 N=81 ERIC TP53 Survey
25 N=81 ERIC TP53 Survey - PARTICIPANTS
26 ERIC TP53 Survey - CLINICIANS N=33 N=33
27 N=55 ERIC TP53 Survey - DIAGNOSTICIANS
28 ACKNOWLEDGEMENTS Jitka Malčíková Šárka Pavlová Karla Plevová Karol Pál Boris Tichý Michael Doubek Certifying Centers: Stephan Stilgenbauer Eugen Tausch Richard Rosenquist Lesley Ann Sutton Jitka Malčíková Natalie Sorolla Training Centers Representatives Paolo Ghia Kostas Stamatopoulos Arnon Kater Carol Moreno Emili Montserrat Natalie Sorolla - ERIC office THANK YOU FOR YOUR ATTENTION!
BASIC PROCEDURES SAMPLING, MATERIAL, SANGER SEQUENCING
Technical aspects of TP53 mutation analysis: BASIC PROCEDURES SAMPLING, MATERIAL, SANGER SEQUENCING Sarka Pavlova University Hospital and Masaryk University, Brno, Czech republic TP53 gene in CLL: KEEP
More informationUpdate on the ERIC TP53 Network Activities and TP53 Certification Overview and Results of Round 4
Update on the ERIC TP53 Network Activities and TP53 Certification Overview and Results of Round 4 Sarka Pospisilova Jitka Malcikova CEITEC, Masaryk University and University Hospital Brno, Czech Republic
More informationTP53 Certification overview and results of round 3
TP53 Certification overview and results of round 3 Sarka Pospisilova Jitka Malcikova CEITEC, Masaryk University and University Hospital, Brno, Czech Rep. 41st ERIC General Assembly, Copenhagen, June 9th,
More informationTP53 ABERRATIONS Methodical considerations
TP53 ABERRATIONS Methodical considerations Sarka Pavlova University Hospital and Masaryk University, Brno, Czech republic Belgrade March 16-17, 2018 TP53 gene in CLL: modes of inactivation mutation(s)
More informationReporting TP53 gene analysis results in CLL
Reporting TP53 gene analysis results in CLL Mutations in TP53 - From discovery to clinical practice in CLL Discovery Validation Clinical practice Variant diversity *Leroy at al, Cancer Research Review
More informationIgCLL group activities in 2009 and beyond. Kostas Stamatopoulos Hematology Department and HCT Unit George Papanicolaou Hospital, Thessaloniki, Greece
IgCLL group activities in 2009 and beyond Kostas Stamatopoulos Hematology Department and HCT Unit George Papanicolaou Hospital, Thessaloniki, Greece Troubleshooting Standardization Standardization and
More information39 th General Assembly of ERIC members. Sunday, 6 th of December 2015 (Orlando, Florida)
39 th General Assembly of ERIC members Sunday, 6 th of December 2015 (Orlando, Florida) Agenda 07:30 08:00 EXECUTIVE COMMITTEE REPORT Introduc>on, membership update and ERIC ac>vi>es during 2015 P. Ghia
More informationTP53 mutational profile in CLL : A retrospective study of the FILO group.
TP53 mutational profile in CLL : A retrospective study of the FILO group. Fanny Baran-Marszak Hopital Avicenne Bobigny France 2nd ERIC workshop on TP53 analysis in CLL, Stresa 2017 TP53 abnormalities :
More informationTranslocations and clonality detection in lymphoproliferative disorders by capturebased Next-generation sequencing
Translocations and clonality detection in lymphoproliferative disorders by capturebased Next-generation sequencing Dörte Wren MSc MPhil on behalf of the EuroClonality-NGS consortium Molecular Diagnostics
More informationChromosome Banding Analysis in CLL Panagiotis Baliakas, MD-PhD
Chromosome Banding Analysis in CLL Panagiotis Baliakas, MD-PhD Dept of Immunology, Genetics and Pathology Science for Life Laboratory, Uppsala University Medical Genetics, University Hospital, Uppsala
More informationBiomarkers in Chronic Lymphocytic Leukemia: the art of synthesis. CLL Immunogenetics. Overview. Anastasia Chatzidimitriou
Biomarkers in Chronic Lymphocytic Leukemia: the art of synthesis CLL Immunogenetics Overview Anastasia Chatzidimitriou Belgrade March 17, 2018 B cells: multiple receptors B cell receptor IG unique signature
More informationPrevalence of BTK and PLCγ2 Mutations in Patients relapsing under Ibrutinib. Lydia Scarfò Silvia Bonfiglio Lesley Ann Sutton
Prevalence of BTK and PLCγ2 Mutations in Patients relapsing under Ibrutinib Lydia Scarfò Silvia Bonfiglio Lesley Ann Sutton Patients relapsing on ibrutinib are the new unmet clinical need Woyach J et al.
More informationAuthor Version: Published ahead of online first
AUTHOR VERSION Author Version: Published ahead of online first ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia update on methodological approaches and results interpretation
More informationERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2018 ERIC recommendations for TP53 mutation analysis in chronic lymphocytic
More informationImportance of minor TP53 mutated clones in the clinic
Importance of minor TP53 mutated clones in the clinic Davide Rossi, M.D., Ph.D. Hematology IOSI - Oncology Institute of Southern Switzerland IOR - Institute of Oncology Reserach Bellinzona - Switzerland
More informationCLL Ireland Information Day Presentation
CLL Ireland Information Day Presentation 5 May 2018 Professor Patrick Thornton Consultant Haematologist, Senior Lecturer RCSI, and Clinical Director Hermitage Medical Clinic Laboratory Chronic Lymphocytic
More information1. What to test. 2. When to test
Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Impact of CLL biological features on
More informationSupplemental data. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic. leukemia
Supplemental data EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia Emma Young 1*, Daniel Noerenberg 2*, Larry Mansouri 1, Viktor Ljungström 1, Mareike Frick 2,
More informationChronic lymphocytic leukemia is eradication feasible and worthwhile?
Chronic lymphocytic leukemia is eradication feasible and worthwhile? Gianluca Gaidano, MD, PhD Division of Hematology Department of Clinical and Experimental Medicine Amedeo Avogardo University of Eastern
More informationCLL Biology and Initial Management. Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology
CLL Biology and Initial Management Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology CLL- Epidemiology Most common adult leukemia 25-30% in western world Incidence in US 4.5
More informationMEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)
Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Ordering Information Acceptable specimen types: Fresh blood sample (3-6 ml EDTA; no time limitations associated with receipt)
More informationPROGNOSTICATION IN CLL: PRESENT AND FUTURE
PROGNOSTICATION IN CLL: PRESENT AND FUTURE Gianluca Gaidano, M.D., Ph.D. Division of Hematology Department of Translational Medicine Amedeo Avogadro University of Eastern Piedmont Novara-Italy CLL: Homogeneous
More information13-ICML SATELLITE SYMPOSIA PROGRAMS (updated on May 9, 2015)
Hematological Oncology Hematol Oncol 2015; 33: 333 344 Published online in Wiley Online Library (wileyonlinelibrary.com).2231 Supplement Article 13-ICML SATELLITE SYMPOSIA PROGRAMS (updated on May 9, 2015)
More informationREAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA.
REAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA Roberta Murru Struttura Complessa Ematologia e Centro Trapianti Presidio Ospedaliero
More informationTHE UMD TP53 MUTATION DATABASE UPDATES AND BENEFITS. Pr. Thierry Soussi
THE UMD TP53 MUTATION DATABASE UPDATES AND BENEFITS Pr. Thierry Soussi thierry.soussi@ki.se thierry.soussi@upmc.fr TP53: 33 YEARS AND COUNTING STRUCTURE FUNCTION RELATIONSHIP OF WILD AND MUTANT TP53 1984
More information3rd Meeting of the European Research Initiative on CLL (ERIC) during the 10th Meeting of the International Working Group on CLL (IWCLL)
3rd Meeting of the European Research Initiative on CLL (ERIC) during the 10th Meeting of the International Working Group on CLL (IWCLL) Stresa, Italy Regina Palace Hotel Thursday, 9 October 2003, 18.00-21.00
More informationAdvances in the treatment of Chronic Lymphocytic Leukemia
Advances in the treatment of Chronic Lymphocytic Leukemia Lab of B Cell Neoplasia - Division of Experimental Oncology Strategic Research Program on CLL Department of Onco-Hematology Università Vita-Salute
More informationTable Of Content. European surveillance of travel associated legionnaires' disease... 2 Summary... 3 Coordinator, Leader contact and partners...
Table Of Content European surveillance of travel associated legionnaires' disease... 2 Summary... 3 Coordinator, Leader contact and partners... 5 Statens Serum Institute... 5 National Environmental Health
More informationChronic lymphocytic leukemia
Chronic lymphocytic leukemia Heterogeneous course Heterogeneouse response to therapy What is the biological basis for this variability? Prognostic markers Choice of therapy Development of new treatment
More informationCross Border Genetic Testing for Rare Diseases
Cross Border Genetic Testing for Rare Diseases EUCERD Joint Action WP8 Helena Kääriäinen National Institute for Health an Welfare, Helsinki, Finland Starting point Possibilities and demand for genetic
More informationSmokefree Policies in Europe: Are we there yet?
Smokefree Policies in Europe: Are we there yet? 14 April 2015, 9:00 10:30am Rue de l Industrie 24, 1040 Brussels Permanent Partners: Temporary Partners: The research for the SFP Smokefree Map was partially
More informationMutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53
GENETICS OF CHRONIC LYMPHOCYTIC LEUKEMIA AND LYMPHOPLASMACYTIC LYMPHOMA Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53 Clive S. Zent 1 and
More informationOverview of European Consumption Databases
FEDERAL INSTITUTE FOR RISK ASSESSMENT Overview of European Consumption Databases Katrin Büsch Workshop Food Consumption Data and Dietary Exposure in the European Union, 15-16 May 2008, Berlin Introduction
More informationChronic lymphocytic Leukemia
Chronic lymphocytic Leukemia after IwCLL, ICML and EHA 2017 Ann Janssens, MD, PhD Hematology, UZ Leuven Brussels, 14 september 2017 Front line treatment CLL Active or progressive disease No active or progressive
More information10 5 TH TH WORKSHOP INTERNATIONAL WORKSHOP ON CO-INFECTION NEW ANTIVIRALS IN CLINICAL PRACTICE HIV & HEPATITIS AMSTERDAM, PARIS, FRANCE THE NETHERLANDS 12-13 JUNE 2014 4-5 DECEMBER 2015 MEETING PROSPECTUS
More informationFORUM FOR AEROSPACE NDT BOARDS
FORUM FOR AEROSPACE NDT BOARDS An overview of the activities of the Forum for National Aerospace NDT Boards ANDTBF/04; Rev: 2010-06-08 What is a NANDTB? EASA regulations part 145 (covering NDT in maintenance)
More informationCurrent dietary habits in Europe far from plant based eating
Current dietary habits in Europe far from plant based eating Stefaan De Henauw Ghent University Department of Public Health Stefaan.dehenauw@ugent.be The menu What is plant based diet? Nutrition transition
More informationCLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, Chronic Lymphocytic Leukemia. Paolo Ghia
CLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, 2013 Chronic Lymphocytic Leukemia Paolo Ghia CLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, 2013
More informationEmerging Risks Mapping of Activities in Member States. 67th Advisory Forum meeting, Utrecht, The Netherlands, 6 February 2018
Emerging Risks Mapping of Activities in Member States 67th Advisory Forum meeting, Utrecht, The Netherlands, 6 February 2018 BACKGROUND 67 th Advisory Forum Meeting, Utrecht, The Netherlands, 6 February
More informationUpdate on the International Harmonised Approach for Residual Disease Monitoring in Chronic Lymphocytic Leukaemia: 8-CLR flow cytometry
Update on the International Harmonised Approach for Residual Disease Monitoring in Chronic Lymphocytic Leukaemia: 8-CLR flow cytometry Andy C. Rawstron on behalf of ERIC consortium Timeline for development
More informationInfectious Disease Testing. ULTRA Product Line. Safety is not a Matter of Chance
Infectious Disease Testing ULTRA Product Line Safety is not a Matter of Chance ULTRA Product Line The best answer for HBV, HCV and HIV screening: a global automated solution for safe results. Monolisa
More informationSubmitted to Leukemia as a Letter to the Editor, May Male preponderance in chronic lymphocytic leukemia utilizing IGHV 1-69.
Submitted to Leukemia as a Letter to the Editor, May 2007 To the Editor, Leukemia :- Male preponderance in chronic lymphocytic leukemia utilizing IGHV 1-69. Gender plays an important role in the incidence,
More informationMEDICAL GENOMICS LABORATORY. Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG)
Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG) Ordering Information Acceptable specimen types: Blood (3-6ml EDTA; no time limitations associated with receipt) Saliva (OGR-575 DNA Genotek;
More informationTemplate for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version: CLLBiomarkers 1.0.0.2 Protocol Posting Date: June 2017
More informationMolecular monitoring of CML patients
EHA, Education Session, CML Stockholm, 14 June 2013 Molecular monitoring of CML patients Martin C. Müller Medical Faculty Mannheim Ruprecht-Karls-University Heidelberg Mannheim, Germany Disclosures Research
More informationD7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells
Disclaimer: The content of this Deliverable represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the
More informationD7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells
Disclaimer: The content of this Deliverable represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the
More informationEuropean Community Pharmacy: a reference in Public Health
European Community Pharmacy: a reference in Public Health Ilaria Passarani PGEU Secretary General 4 October 2018, Burgos, Spain Pharmaceutical Group of European Union Members: Professional Bodies & Pharmacists
More informationCirculating Galectin-3 as a Prognostic. Biomarker in Patients with Chronic. Lymphocytic Leukemia
Biological Markers and Guided Therapy, Vol. 2, 2015, no. 1, 69-77 HIKARI Ltd, www.m-hikari.com http://dx.doi.org/10.12988/bmgt.2015.5116 Circulating Galectin-3 as a Prognostic Biomarker in Patients with
More informationInitial Diagnosis and Treatment 81 Male
Case SH2017-0359 Shiraz Fidai 1, Sandeep Gurbuxani 1, Girish Venkataraman 1, Gordana Raca 2, Madina Sukhanova 3, Michelle M Le Beau 3, Y. Lynn Wang 4, Mir Alikhan 4, Megan M.McNerney 4, Yuri Kobzev 4,
More informationBio-Rad Laboratories HEMOGLOBIN Testing Bio-Rad A1c. VARIANT II TURBO Link. Fully-Automated HbA 1c Testing
Bio-Rad Laboratories HEMOGLOBIN Testing Bio-Rad A1c VARIANT II TURBO Link Fully-Automated HbA 1c Testing Bio-Rad Laboratories HEMOGLOBIN Testing VARIANT II TURBO Link Efficient streamlined process Powerful
More informationWCPT COUNTRY PROFILE December 2017 HUNGARY
WCPT COUNTRY PROFILE December 2017 HUNGARY HUNGARY NUMBERS WCPT Members Practising physical therapists 727 Total number of physical therapist members in your member organisation 4,000 Total number of practising
More informationEuropean Partnership for Screening
European Partnership for Screening Lawrence von Karsa Quality Assurance Group European Cancer Network for Screening and Prevention International Agency for Research on Cancer Lyon, France Work Package
More informationBiology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?
Biology Report Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis? Introduction Tuberculosis is a serious disease caused by the bacterium Mycobacterium
More informationBio-Rad Laboratories HEMOGLOBIN Testing Bio-Rad A1c. VARIANT II TURBO Link System. Fully-Automated HbA 1c Testing
Bio-Rad Laboratories HEMOGLOBIN Testing Bio-Rad A1c VARIANT II TURBO Link System Fully-Automated HbA 1c Testing Bio-Rad Laboratories HEMOGLOBIN Testing VARIANT II TURBO Link System Efficient streamlined
More informationWCPT COUNTRY PROFILE December 2017 SWEDEN
WCPT COUNTRY PROFILE December 2017 SWEDEN SWEDEN NUMBERS WCPT Members Practising physical therapists 11,043 Total number of physical therapist members in your member organisation 17,906 Total number of
More informationLEBANON. WCPT COUNTRY PROFILE December 2018
LEBANON WCPT COUNTRY PROFILE December 2018 LEBANON NUMBERS 1600 1400 1200 1000 800 600 400 200 0 Physical therapists in the country Members in MO 1,480 1,480 Total PTs in country 800000 700000 600000 500000
More informationCLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler
CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer
More informationEFSA s Concise European food consumption database. Davide Arcella Data Collection and Exposure Unit
EFSA s Concise European food consumption database Davide Arcella Data Collection and Exposure Unit 1 The EFSA raison d être Risk assessment authority created in 2002 as part of a comprehensive program
More informationWhere we stand in EFORT
Where we stand in EFORT Engaging with the new EU regulatory landscape for medical devices. Challenges & opportunities Brussel, Belgium April 6, 2018 Per Kjaersgaard-Andersen Associate Professor Section
More informationEngagement in language assessment / Regions of Europe
Summary table: Engagement in language / Regions of This table lists the statistically significant differences in the engagement in activities by the respondents from different s of : If the word or appears
More informationDENMARK. WCPT COUNTRY PROFILE December 2018
DENMARK WCPT COUNTRY PROFILE December 2018 DENMARK NUMBERS 14000 12000 10000 8000 6000 4000 2000 0 Physical therapists in the country Members in MO 11,720 12,975 Total PTs in country 800000 700000 600000
More informationWCPT COUNTRY PROFILE December 2017 SERBIA
WCPT COUNTRY PROFILE December 2017 SERBIA SERBIA NUMBERS WCPT Members Practising physical therapists 622 Total number of physical therapist members in your member organisation 3,323 Total number of practising
More informationOutcome of proficiency test on EIA serology
Outcome of proficiency test on EIA serology Anses Dozulé Laboratory for equine diseases VIPARE unit Delphine Gaudaire EIA PT GENERAL INFORMATION AIM OF THE PT Detect EIA antibodies: using Agar Gel Immuno-Diffusion
More informationThe feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients
The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients ASSC Scientific Meeting 13 th October 2016 Prof Andrew Barbour UQ SOM
More informationWESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017
WESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017 Mary L. Yost 404-520-6652 , LLC 23 Ridge Rd. Beaufort, SC 20097 Copyright Pending 2017 All rights reserved,
More informationSecond announcement. In addition, a pre-conference workshop on Lipidomics for biomarker and clinical analysis will take place during July 1-3, 2014.
Second announcement International conference: Healthcare integrated biobanking and multiomics biomarker analysis (July 3-5, 2014) Workshop: Lipidomics for biomarker and clinical analysis (July 1-3, 2014)
More informationMEETING PROSPECTUS www.virology-education.com CONTENT Introduction... 3 Workshop description... 4 Background...4 Meeting Objectives...4 Learning Objectives...4 Format...4 Unique Meeting Features...4 Target
More informationREPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS
EUROPEAN COMMISSION Brussels, 17.6.011 COM(011) 35 final REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS
More informationEpigenetic programming in chronic lymphocytic leukemia
Epigenetic programming in chronic lymphocytic leukemia Christopher Oakes 10 th Canadian CLL Research Meeting September 18-19 th, 2014 Epigenetics and DNA methylation programming in normal and tumor cells:
More informationRecurrent gene mutations in chronic lymphocytic leukemia: An ERIC project within HARMONY
Bench to Bedside Project Recurrent gene mutations in chronic lymphocytic leukemia: An ERIC project within HARMONY Lesley Ann Sutton Uppsala Universitet Sweden 43 rd ERIC GENERAL ASSEMBLY HARMONY: A European
More informationFeedback from the Member States questionnaire
Annex 6 Feedback from the Member States questionnaire Reinhilde A.R. Schoonjans Special meeting of the EFSA Advisory Forum on GMO risk assessment in Europe 13 November 2007, Brussels Topics 1. Highlights
More informationGERMANY. WCPT COUNTRY PROFILE December 2018
GERMANY WCPT COUNTRY PROFILE December 2018 GERMANY NUMBERS 160000 140000 120000 100000 80000 60000 40000 20000 0 Physical therapists in the country Members in MO 21,502 136,000 Total PTs in country 800000
More informationEUVAC.NET A surveillance network for vaccine-preventable diseases
EUVAC.NET A surveillance network for vaccine-preventable diseases Mark Muscat EUVAC.NET Co-ordinator Department of Epidemiology Statens Serum Institut Denmark Email: mmc@ssi.dk Viral Hepatitis Prevention
More informationBio-Rad Laboratories. Hemoglobin Testing. VARIANT II Hemoglobin Testing System For HbA 1c
Bio-Rad Laboratories Hemoglobin Testing VARIANT II Hemoglobin Testing System For HbA 1c Bio-Rad CDM System CDM 5.1 VII Instrument Patient Report V2_A1c_NU Patient Data Sample ID: AD Patient ID: Name: Physician:
More informationAVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect
More informationCurrent levels and recent trends in health inequalities in the EU: Updates from the EU Report
Current levels and recent trends in health inequalities in the EU: Updates from the EU Report Anne Scott London Health Observatory Expert Working Group on Social Determinants and Health Inequalities Luxembourg,
More informationMolecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note
Molecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note MPEP/MPC Advice Note 2016-02 June 2016 Test evaluated: Tumour Protein p53 (TP53) Molecular Pathology Evaluation Panel
More informationreal-time AQ data 2007 and plans for 2008
real-time AQ data 2007 and plans for 2008 Tim Haigh - project manager Information Resources http://www.eea.europa.eu/maps/ozone/map/ Where is all the data coming from? EEA NRT Database 4000 2000 700 EEA
More informationA European Union-wide slaughterhouse baseline survey on the prevalence of Salmonella in slaughter pigs
A European Union-wide slaughterhouse baseline survey on the prevalence of Salmonella in slaughter pigs Pierre-Alexandre Belœil Zoonoses Data Collection Unit Workshop on Salmonella control in pigs Brussels
More informationWhat s s on the Menu in Europe? - overview and challenges in the first pan- European food consumption survey
What s s on the Menu in Europe? - overview and challenges in the first pan- European food consumption survey Liisa Valsta Data Collection and Exposure Unit What s s on the menu in Europe? Background Attempts
More informationIntroduction CLINICAL TRIALS AND OBSERVATIONS
CLINICAL TRIALS AND OBSERVATIONS Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21
More informationAnalysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers
Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers Gordon Blackshields Senior Bioinformatician Source BioScience 1 To Cancer Genetics Studies
More informationPriv.Doz. Dr. Ulrich Wedding Universitätsklinikum Jena, Klinik für Innere Medizin II Jena, Germany SIOG CLL TASKFORCE
Priv.Doz. Dr. Ulrich Wedding Universitätsklinikum Jena, Klinik für Innere Medizin II Jena, Germany SIOG CLL TASKFORCE Achieve an expert recommendation/consensus on appropriate treatment strategy on CLL
More informationProject Meeting Prague
Project Meeting Prague IO1 Assessment 9.11.217 CHRISTINA PADBERG ON BEHALF OF FRANKFURT UAS Current Status Assessment matrix was fully evaluated Experts have been interviewed, Interviews were fully evaluated
More informationNGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation
NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation Michael R. Rossi, PhD, FACMG Assistant Professor Division of Cancer Biology, Department of Radiation Oncology Department
More informationTrends in mortality from leukemia in subsequent age groups
(2000) 14, 1980 1985 2000 Macmillan Publishers Ltd All rights reserved 0887-6924/00 $15.00 www.nature.com/leu Trends in mortality from leukemia in subsequent age groups F Levi 1, F Lucchini 1, E Negri
More informationNote on the harmonisation of SILC and EHIS questions on health
EUROPEAN COMMISSION EUROSTAT Directorate F: Social statistics and Information Society Unit F-5: Health and food safety statistics 23/01/2008 Note on the harmonisation of SILC and EHIS questions on health
More informationResults you can trust
PRODUCT I NF OR MAT ION pharmdx Results you can trust The first and only FDA-approved PD-L1 test to assess the magnitude of treatment effect on progression-free survival in melanoma patients from OPDIVO
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES
COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 22.12.2008 COM(2008) 882 final REPORT FROM THE COMMISSION TO THE COUNCIL, THE EUROPEAN PARLIAMENT, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE
More information8 th Congress of ECCO
European Crohn s and Colitis Organisation Vienna Austria 8 th Congress of ECCO Austria Center Vienna February 14-16, 2013 The major educational event in the field of Inflammatory Bowel Diseases in Europe
More informationThe mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment
INDIVIDUALIZING THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment Gianluca Gaidano 1 and Davide Rossi 2,3 1 Division
More informationA continuous Educational Programme from Basic Immunology to Clinical Neuroimmunology PROFILE 2017
A continuous Educational Programme from Basic Immunology to Clinical Neuroimmunology PROFILE 2017 ABOUT US Gianvito Martino (for the Scientific Committee) It is a pleasure to introduce this new, exciting
More information